This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

Consider IPD protection when it matters

Early protection matters in the first year of life when the risk of pediatric IPD is the highest1-3

The incidence of IPD in children was ~2x as high in the first year of life than that of children 1-4 years of age combined.1,a

The death rate due to IPD was at least 2x as high in infants than in any other pediatric age group.1,b

aBased on pooled analysis of national-level CDC ABC surveillance data from 2019–2023, representing ~35 million people surveyed annually in 10 states across the US. Regional variations may exist. IPD incidence rates were 10.3 in <1 year, 8.0 in 1 year, 4.6 in 2–4 years, 5.5 in 1–4 years, and 1.4 in 5–17 years.1

bBased on pooled analysis of national-level CDC ABC surveillance data from 2019–2023, representing ~35 million people in 10 states across the US. Regional variations may exist. Rates of death per 100,000 population for ABCs areas were 0.62 in <1 year, 0.15 in 1 year, 0.28 in 2–4 years, and 0.06 in 5–17 years. For each age group during 2019–2023, deaths within the ABCs areas and national estimates, respectively, were in <1 year: ABCs areas: 12 deaths in 1,945,628 persons, national estimate: ~113 deaths in 18,392,796 persons; in 1 year: ABCs areas: 3 deaths in 1,965,119 persons, national estimate: ~28 deaths in 18,625,903 persons; in 2–4 years: ABCs areas: 17 deaths in 6,054,551 persons, national estimate: ~163 deaths in 58,047,830 persons; in 5–17 years: ABCs areas: 18 deaths in 28,391,356 persons, national estimate: ~173 deaths in 272,550,379.1

PCVs are CDC recommended as a 4-dose series2

2 Months: 1st Dose(a,b); 4 Months: 2nd Dose(b); 6 Months: 3rd Dose(b); Infants Must Wait At Least 6-9 Months After the Last Infant Dose Until They're Able to Receive Their Toddler Dose; 12-15 Months: 4th Dose(c)2 Months: 1st Dose(a,b); 4 Months: 2nd Dose(b); 6 Months: 3rd Dose(b); Infants Must Wait At Least 6-9 Months After the Last Infant Dose Until They're Able to Receive Their Toddler Dose; 12-15 Months: 4th Dose(c)

cDose 1 may be given as early as 6 weeks of age.

dThe recommended interval between doses is 4 to 8 weeks.

eThe 4th dose should be administered at approximately 12 through 15 months of age and at least 2 months after the 3rd dose.

Despite the CDC’s recommendation, not all babies complete the 4-dose series.2,4,5,f

Approximately 19% of Babies Overall and 42% of Babies in the VFC Program Received 3 or Fewer of the CDC Recommended PCV 4-Dose Series by 2 Years of AgeApproximately 19% of Babies Overall and 42% of Babies in the VFC Program Received 3 or Fewer of the CDC Recommended PCV 4-Dose Series by 2 Years of Age

fNIS-Child, a random digit-dialed telephone survey of parents/guardians of children aged 19–35 months that the CDC used to estimate the vaccination coverage with ACIP-recommended vaccines in the US among children born in 2020 and 2021.4

ABC, Active Bacterial Core; ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; NIS-Child, National Immunization Survey – Child; VFC, Vaccines for Children.

Stay updated on serotypes

Stay updated on serotypes

See immunogenicity data

See immunogenicity data

Learn about special populations

Learn about special populations

View safety & tolerability data

View safety & tolerability data

References:

  1. Active Bacterial Core surveillance (ABCs). Surveillance reports. Centers for Disease Control and Prevention. Updated August 21, 2025. Last accessed August 28, 2025. https://www.cdc.gov/abcs/reports/index.html
  2. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Revised October 7, 2025. Accessed October 12, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
  3. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed August 2021. Accessed May 16, 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html
  4. Hill HA, et al. Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 — National Immunization Survey-Child, United States, 2021–2023. MMWR Morb Mortal Wkly Rep, pages 844–853.
  5. Centers for Disease Control and Prevention (CDC). Supplementary Table 1. Estimated vaccination coverage by age 24 months* among children born during 2020-2021,† by selected vaccines and doses and health insurance status§ – National Immunization Survey- Child, United States, 2021-2023. MMWR. 2024;73(38). Accessed January 22, 2025. https://stacks.cdc.gov/view/cdc/162213

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage
Select Safety Information

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.